Mahmoud Alhariri: Apixaban in Hemodialysis-Treated Kidney Failure With Newly Diagnosed AF
Mahmoud Alhariri, Senior Attending Physician at Helios Universitätsklinikum Wuppertal, Hypertensiologe at Deutsche Hochdruckliga e.V. DHL, Lipidology Specialist at Deutsche Gesellschaft für Lipidologie e. V. (DGFL), shared a post on LinkedIn about a recent article by Wolfgang C. Winkelmayer et al., published in American Journal of Kidney Diseases, adding:
“Among patients with hemodialysis-treated kidney failure, compared with no anticoagulation, initiation of apixaban soon after newly diagnosed AF was associated with lower risks of ischemic stroke, a composite thromboembolic end point, and all-cause mortality but higher rates of clinically meaningful bleeding.”
Title: Effectiveness and Safety of Apixaban Initiation Following Newly-Diagnosed Atrial Fibrillation in Patients With Kidney Failure on Hemodialysis
Authors: Wolfgang C. Winkelmayer, Kevin F. Erickson, Pascale Khairallah, Mingyue He, Maria E. Montez-Rath, Tara I. Chang, Jingbo Niu

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome